Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Addiction

US pharmacists to get opioid addiction training

Dr Scott Gottlieb, FDA Commissioner

Source: Rex / Shutterstock

FDA commissioner Dr Scott Gottlieb said that for the first time, the FDA will be asking for the training on appropriate prescribing of opioid medicines to be made available to other non-physicians, including pharmacists.

US drug regulators have called for pharmacists to have access to training on appropriate prescribing of opioid medicines to help tackle addiction.

To help reduce the rate of new addictions, the Food and Drug Administration (FDA) put in place a Risk Evaluation and Mitigation Strategy (REMS) for extended-release/long-acting opioid analgesics on 9 July 2012.

The regulator is now updating the scheme, which aims to ensure that opioid use is restricted to appropriate indication, duration, and dose, to include immediate-release opioid analgesic products.

In a statement, FDA commissioner Dr Scott Gottlieb said that for the first time, the FDA will be asking that the training be made available to other non-physicians, including pharmacists and nurses.

The FDA is currently considering whether such training, which is being expanded to include “broader information on pain management and enhanced information about the safe use of opioid analgesics, basic elements of addiction medicine and opioid use disorders,” should be mandatory.

In a response to a report on the evidence of opioid addiction from the National Academies of Sciences, Engineering, and Medicine, Gottlieb said the Administration was reassessing what further steps could be taken to reduce exposure to the drugs.

This includes incorporating a ‘benefit–risk framework’ into decisions on opioid drug approval and removal to include the public health impact of inappropriate use of the drugs.

He also said the FDA was encouraging the development of new treatment options for pain and continuously re-evaluating the safety of approved opioids through post-market data and safety surveillance.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203208

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Dr Scott Gottlieb, FDA Commissioner

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.